Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus

被引:2
|
作者
Pereyra-Rodriguez, Jose J. [1 ]
Baldrich, Esther S. [2 ,11 ]
Ruiz-Villaverde, Ricardo [3 ]
Torres, Eulalia B. [4 ]
Dobao, Pablo De La C. [5 ]
Nart, Ignasi F. [6 ]
Menendez, Angeles F. [7 ]
Martin-santiago, Ana [8 ]
Miquel, Javier M. [9 ]
Silvestre, Juan F. [10 ]
Armario-Hita, Jose C.
机构
[1] Univ Seville, Sch Med, Dept Dermatol, Seville, Spain
[2] Santa Creu & St Pau Hosp, Dept Dermatol, Barcelona, Spain
[3] Clin San Cecilio Univ Hosp, Dept Dermatol, Granada, Spain
[4] St Joan Deu Hosp, Dept Dermatol, Barcelona, Spain
[5] Infanta Leonor Univ Hosp, Dept Dermatol, Madrid, Spain
[6] Bellvitge Univ Hosp, Dept Dermatol, Barcelona, Spain
[7] Pontevedra Univ Hosp, Dept Dermatol, Pontevedra, Spain
[8] Son Espases Univ Hosp, Dept Dermatol, Palma De Mallorca, Spain
[9] Arnau Vilanova Hosp, Dept Dermatol, Valencia, Spain
[10] Alicante Univ Gen Hosp, Dept Dermatol, Alicante, Spain
[11] Hosp Santa Creu & Sant Pau, Dermatol Dept, St Antoni Maria Claret 167, ES-08025 Barcelona, Spain
关键词
atopic dermatitis; immunoglobulin E; biological agents; type 2 inflammatory diseases; TOPICAL CALCINEURIN INHIBITORS; GUIDELINES; ECZEMA; SENSITIZATION; METAANALYSIS; BIOMARKERS; ALLERGY; ADULTS;
D O I
10.2340/actadv.v103.12314
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Despite emerging evidence and advances in the management of atopic dermatitis there a lack of consensus regarding the diagnostic criteria, therapeutic approach, method to assess severity, and patient follow-up for this condition. An expert consensus study was conducted to provide recommendations on the management of patients with moderate-to-severe atopic dermatitis. The study used Delphi-like methodology based on a literature review, a summary of the scientific evidence, and a 2-round survey. The agreement of 60 panellists on 21 statements was evaluated. Consensus was predefined as >= 80% agreement of all respondents. In the first round 6 statements reached consensus. Unanimous consensus was achieved regarding therapeutic goals and patient satisfaction (maintained in the long term and periodic goals reassessment recommended every 3-6 months). In the second round, half of the statements reached consensus, all related to patient follow-up, treatment goals, and atopic comorbidities. The statements that did not reach consensus were related to diagnosis (biomarkers, allergy, and food testing) and starting patients on conventional systemic treatment rather than advanced treatment. The study assessed expert opinion regarding a variety of topics related to the clinical approach to patients with moderate-to-severe atopic dermatitis, in order to provide guidance on the diagnosis and management of patients with atopic dermatitis.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [22] Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity
    Dupuis, Josephine
    Tauber, Marie
    Mahe, Emmanuel
    Jachiet, Marie
    Soria, Angele
    Tetart, Florence
    Puzenat, Eve
    Pasteur, Justine
    Raison-Peyron, Nadia
    Giordano-Labadie, Francoise
    Droitcourt, Catherine
    Leleu, Camille
    Nosbaum, Audrey
    Aubert, Helene
    Moigne, Marie L. E.
    Bernier, Claire
    Barbarot, Sebastien
    Ezzedine, Khaled
    Diaz, Emmanuelle
    Hubiche, Thomas
    Faiz, Sarah
    Azib, Selma
    Dezoteux, Frederic
    Chosidow, Olivier
    Staumont-Salle, Delphine
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (02) : e174 - e178
  • [23] Ocular surface disease is common in moderate-to-severe atopic dermatitis patients
    Achten, Roselie E.
    Bakker, Daphne S.
    van Luijk, Chantal M.
    van Der Wal, Marlot
    de Graaf, Marlies
    van Wijk, Femke
    Zuithoff, Nicolaas P. A.
    van Der Rijst, Lisa P.
    Boesjes, Celeste M.
    Thijs, Judith L.
    de Boer, Joke H.
    de Bruin-Weller, Marjolein S.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (06): : 801 - 805
  • [24] Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Facheris, Paola
    Gomez-Arias, Pedro Jesus
    Del Duca, Ester
    Da Rosa, Joel Correa
    Weidinger, Stephan
    Bissonnette, Robert
    Armstrong, April W.
    Seneschal, Julien
    Eyerich, Kilian
    Estrada, Yeriel D.
    Bose, Swaroop N.
    Xu, Dan
    Chen, Allshine
    Tatulych, Svitlana
    Guler, Erman
    Chan, Gary
    Page, Karen M.
    Kerkmann, Urs
    ALLERGY, 2024, 79 (05) : 1258 - 1270
  • [25] Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
    Schloesser, Anne R.
    Shareef, Madena
    Olydam, Jill
    Nijsten, Tamar E. C.
    Hijnen, Dirk Jan
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (05) : 510 - 517
  • [26] Treatment satisfaction in patients receiving dupilumab for moderate-to-severe atopic dermatitis
    Lans, A.
    Van der Schaft, J.
    Bakker, D.
    Ariens, L.
    Thijs, J. H.
    De Bruin-Weller, M. S.
    Balak, D. M. W.
    ALLERGY, 2019, 74 : 82 - 82
  • [27] Clinical burden and work productivity impairment in moderate-to-severe atopic dermatitis patients in the United States
    Feldman, Steven R.
    Guerin, Annie
    Gauthier-Loiselle, Marjolaine
    Claxton, Ami J.
    Hazra, Nisha C.
    Meng, Yan
    Gallant, Kirsten
    Balu, Sanjeev
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II45 - II46
  • [28] Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis
    Weidinger, Stephan
    Cork, Michael
    Reich, Adam
    Bieber, Thomas
    Gilbert, Sally
    Quaratino, Sonia
    Wilson, Rosamund
    Porter-Brown, Ben
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [29] Dupilumab treatment induces rapid clinical improvement of itch in patients with moderate-to-severe atopic dermatitis
    Silverberg, Jonathan I.
    Eckert, Laurent
    Ardeleanu, Marius
    Chen, Zhen
    Akinlade, Bolanle
    Plaum, Stefan
    Graham, Neil M. H.
    Pirozi, Gianluca
    Gadkari, Abhijit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB113 - AB113
  • [30] Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis
    Weidinger, Stephan
    Cork, Michael
    Reich, Adam
    Bieber, Thomas
    Gilbert, Sally
    Quaratino, Sonia
    Wilson, Rosamund
    Porter-Brown, Ben
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB221 - AB221